A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. (Q27853079)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. |
scientific article |
Statements
2 references
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma (English)
Ho Yeong Lim
Jeong Heo
Cheng-Yao Lin
Chiun Hsu
Kun-Ming Rau
Ronnie T P Poon
Joong-Won Park
Miah Hiang Tay
Wen-Son Hsieh
Christian Kappeler
Prabhu Rajagopalan
Heiko Krissel
Michael Jeffers
Chia-Jui Yen
Won Young Tak
7 October 2014
Identifiers
2 references
2 references